What
is elvucitabine? •
Elvucitabine is an
anti-HIV medication. It is in a category of HIV medicines called nucleoside reverse
transcriptase inhibitors (NRTIs). Elvucitabine prevents HIV from entering the
nucleus of healthy T-cells. This prevents the cells from producing new virus and
decreases the amount of virus in the body. •
Elvucitabine is being
developed by Achillion Pharmaceuticals. It has not yet been reviewed by the U.S.
Food and Drug Administration.
What
is already known about elvucitabine? •
The necessary dose
of elvucitabine has not yet been determined. However, early research suggests
that it will only need to be taken once a day. •
Like other nucleoside
reverse transcriptase inhibitors (NRTIs), elvucitabine might interact with other
medications, including those used to treat HIV. It is important that your personal
physician and/or the research nurse or study investigator be aware of all drugs
you are taking, including those you buy without a prescription.
